VidPrevtyn Beta is the protein vaccine against the coronavirus – The Commission and Member States have negotiated a pre-purchase agreement with Sanofi and GSK and have the option to buy up to 300 million doses of the vaccine if they wish
The Commission granted a marketing authorization for the vaccine VidPrevtyn Beta as a booster dose. VidPrevtyn Beta is the coronavirus protein vaccine developed by Sanofi and GSK and is the seventh coronavirus vaccine to be approved in the EU. This license covers the use of the vaccine as a booster dose for adults after initial vaccination with another coronavirus vaccine.
The marketing authorization follows the positive scientific recommendation of the European Medicines Agency (EMA), which is based on a thorough evaluation of the safety, efficacy and quality of the vaccine, and has been approved by the Member States. A diversity of options for coronavirus vaccines is essential to ensure citizens are protected. The Commission and Member States negotiated a pre-purchase agreement with Sanofi and GSK, which entered into force on 18 September 2020, and gives EU Member States the option to purchase up to 300 million doses of the vaccine if they wish.
Member States can also use these vaccines for donations in low- and middle-income countries. The EU portfolio now includes seven safe and effective vaccines against the coronavirus.
Read the News today and get the latest news.
Follow Skai.gr on Google News and be the first to know all the news.
As a seasoned news journalist, I bring a wealth of experience to the field. I’ve worked with world-renowned news organizations, honing my skills as a writer and reporter. Currently, I write for the sports section at News Bulletin 247, where I bring a unique perspective to every story.
